The arrival of Retatrutide ZPHC, at a concentration of 120mg, is creating considerable interest within the medical community. This novel dual GIP and GLP-1 target medication seems to deliver impressive improvements in fat loss compared to previous therapies. Preliminary research studies have shown marked reductions in weight read more , potentially